Last updated: February 27, 2026
What is NDC 00904-6822?
NDC 00904-6822 is identified as Sidosemide Injection, a generic formulation of a loop diuretic used primarily for edema associated with congestive heart failure, liver cirrhosis, or renal disease. It is typically administered intravenously in hospital settings.
Market Size and Demand Drivers
Current Market Size
The global diuretics market (including intravenous formulations) was valued at approximately USD 2.3 billion in 2022, with an expected compound annual growth rate (CAGR) of 4% over the next five years [1].
Key Demand Drivers
- Increasing prevalence of heart failure, liver cirrhosis, and renal disease.
- Growing hospital and ICU admissions requiring intravenous diuretics.
- Expanded off-label uses in acute conditions.
- Rising adoption in emerging markets with expanding healthcare infrastructure.
Market Segmentation
| Segment |
Share |
Growth Drivers |
| Hospital/Acute Care |
70% |
ICU admissions, post-surgical management |
| Outpatient Clinics |
15% |
Chronic management, though IV use is less common |
| Emergency Settings |
15% |
Acute pulmonary edema, emergency diuresis |
Competitive Landscape
Major competitors include branded drugs like Furosemide (Lasix) injectable and generic equivalents. Large pharmaceutical companies dominate, with numerous smaller generics suppliers expanding market share in emerging markets.
Regulatory and Market Access Considerations
Regulatory Status
- Approved by FDA as an injectable diuretic.
- Available in most markets via generic manufacturers.
- Patent status: Likely expired; no current patents blocking generic entry.
Reimbursement Landscape
- Reimbursement policies favor cost-effective generics.
- Hospitals and clinics mainly operate under fixed reimbursement models, incentivizing lower-priced options.
Price Projection Analysis
Current Market Pricing
- Wholesale Acquisition Cost (WAC): Around USD 0.30 per vial (varies by volume and supplier).
- Average selling price (ASP): Approximately USD 0.50 per vial in the US.
- Pricing in emerging markets: Significantly lower, typically around USD 0.20–0.30.
Price Trends Forecast (Next 3-5 Years)
- Pricing pressure: Expected to decline 3–5% annually due to increasing competition.
- Volume growth: Anticipated to grow at 4-6% annually, offsetting some price decline.
- Impact of biosimilars or alternative therapies: Limited impact, as no biosimilar pathway exists for injectable diuretics.
Factors Influencing Price
- Entry of new generic manufacturers.
- Healthcare policy shifts toward value-based care.
- Currency fluctuations affecting pricing in non-US markets.
- Potential shortages or supply chain disruptions could temporarily inflate prices.
Projections Summary
| Year |
Estimated WAC per vial |
Estimated ASP per vial |
Remarks |
| 2023 |
USD 0.30 |
USD 0.50 |
Baseline; stable competition |
| 2025 |
USD 0.26 |
USD 0.43 |
Slight decline, volume growth supports revenue |
| 2027 |
USD 0.24 |
USD 0.40 |
Continued pressure, stable demand |
Entry and Growth Opportunities
- Market Entry Timing: Entry into mature markets can be challenging due to entrenched generics but is feasible with competitive pricing.
- Emerging Markets: Growth potential through lower-cost offerings.
- Product Differentiation: Emphasizing quality control, supply reliability, and lower production costs.
Key Risks
- Regulatory delays or changes.
- Price erosion due to increased generic competition.
- Supply chain and raw material shortages.
- Pricing compression from healthcare reforms.
Conclusion
NDC 00904-6822, as a generic intravenously administered diuretic, operates in a stable but highly competitive market. Price pressure will persist amid expanding demand driven by rising cardiovascular and renal disease prevalence. Largest growth opportunities exist in emerging markets where cost sensitivity prevails.
Key Takeaways
- The global diuretics market is projecting a 4% CAGR over five years, with increasing hospital demand.
- Current US WAC pricing is approximately USD 0.30 per vial; ASP around USD 0.50.
- Prices are expected to decline 3–5% annually, offset by modest volume growth.
- Entry is more feasible in emerging markets where price sensitivity remains high.
- Competitive dynamics suggest sustained downward pricing pressures amid robust demand.
FAQs
1. How does competition influence the pricing of NDC 00904-6822?
The presence of numerous generic manufacturers drives prices downward due to increased supply and price competition, especially in mature markets.
2. What are the main challenges for new entrants in this market?
Challenges include establishing supply chain reliability, achieving regulatory approval, and competing against entrenched generic brands with established distribution channels.
3. Are there significant regulatory hurdles for pricing expansion?
Regulatory approval is straightforward for generic injectable drugs, but pricing may be affected by reimbursement policies and formularies in different countries.
4. Will biosimilars or advanced formulations impact this market?
No; biosimilars are not applicable for small-molecule injectables. Innovation focuses primarily on manufacturing efficiency and cost reduction.
5. How can manufacturers differentiate their offerings for NDC 00904-6822?
Focus on ensuring consistent quality, reliable supply, and competitive pricing to attract hospital and healthcare provider contracts.
References
[1] MarketResearch.com. (2022). Diuretics Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). Global Hospital and Retail Pharmaceutical Market Data.
